Whalesbook
Venus Remedies Reports Strong FY26 Performance with 127% Profit Growth
Venus Remedies' consolidated net profit soared 126.84% to ₹102.78 crore for the year ended March 31, 2026, a significant increase from ₹45.31 crore in the previous year. Revenue from operations also grew by 17.88% to ₹769.60 crore.
Key Financial Highlights
Venus Remedies Limited (VRL) announced its audited financial results for the fiscal year ending March 31, 2026. The company's consolidated net profit surged by 126.84% to ₹102.78 crore, boosted by a 17.88% rise in revenue from operations, reaching ₹769.60 crore.
On a standalone basis, net profit grew 89.17% to ₹99.31 crore, with revenue up 19.28% to ₹768.73 crore. The board has recommended a final dividend of ₹10 per equity share, representing a 100% payout.
Why This Matters to Investors
This substantial profit growth highlights improved operational efficiency and strong market performance. The recommended dividend offers a direct financial return to shareholders, enhancing the stock's attractiveness.
Performance Turnaround
In the previous fiscal year, which ended March 31, 2025, Venus Remedies reported a consolidated net profit of ₹45.31 crore on revenues of ₹652.89 crore. The current year's results mark a significant turnaround and accelerated growth.
Recent Developments
Shareholders will await AGM approval for the dividend payout. The company has also made key board appointments and re-appointments. Additionally, new MOA and AOA have been adopted to align with the Companies Act, 2013.
Potential Risks to Monitor
The auditor's report noted that financial statements for foreign subsidiaries, Venus Pharma GmbH and Venus Pharma Kft, were still undergoing audit at the reporting date. The consolidated results' reliance on management-prepared conversion adjustments is a point for investors to consider regarding transparency.
Furthermore, Venus Remedies is restructuring its European operations, with guidance from a German consultancy. Investors should closely watch the progress and financial implications of this strategic move.
Key Metrics
- FY 2025-26 Consolidated Revenue: ₹769.60 crore (up 17.88% year-over-year)
- FY 2025-26 Consolidated Net Profit: ₹102.78 crore (up 126.84% year-over-year)
- FY 2025-26 Standalone Revenue: ₹768.73 crore (up 19.28% year-over-year)
- FY 2025-26 Standalone Net Profit: ₹99.31 crore (up 89.17% year-over-year)
- Recommended Final Dividend: ₹10 per equity share (100% payout)
- Dividend Record Date: August 7, 2026
- AGM Date: August 20, 2026
What to Watch Next
Investors should closely monitor the finalization of foreign subsidiary audits, the outcomes of the European operations restructuring, and the company's broader strategic initiatives.